Skip to Content

MURANO Study Supports the Use of Fixed-Duration VenR in R/R CLL

Final 7-year follow-up findings from the MURANO study were revealed at this EHA 23’ congress. In this MEDtalk, professor of Translational Hematology, Arnon Kater, presents the results indicating meaningful progression-free survival of patients with relapsed/refractory chronic lymphatic leukemia (R/R CLL) treated with venetolax-rituximab (VenR).

Arnon Kater

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top